Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250020/S004

Belotero Volume (+) Lidocaine

Merz North America, Inc. · Decision date Nov 4, 2026

MEDTECHLEDGER EXPLANATIONP250020/S004

What did the FDA approve?

The FDA recorded an approval decision on 2026-11-04 for PMA supplement P250020/S004, submitted by Merz North America, Inc. under the Normal 180 Day Track. The supplement covers Belotero Volume (+) Lidocaine, a dermal implant for aesthetic use (product code LMH), within the general and plastic surgery specialty. The recorded supplement reason is a labeling change affecting indications, instructions, shelf life or tradename.

The stated scope is a change to the release specification and shelf-life specifications for the device. This is a supplement-level decision, not a new approval of the underlying system, and the source record does not describe the revised specification values, the affected shelf-life duration, or any labeling text. No supporting documents were included, so the specific technical content of the change cannot be verified from this record alone.

FDA approval order statement

approval for a change to the release specification and shelf-life specifications for Belotero Volume (+) Lidocaine (BVL) Dermal Filler
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
General, Plastic Surgery
Decision date
Nov 4, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250020/S004
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
APPR
Decision date
Nov 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P250020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250020 · Original PMA

    Belotero Volume (+) Lidocaine

  2. P250020/S004 received

    Application receipt date recorded by FDA.

  3. P250020/S005 · Related supplement

    Belotero Volume (+) Lidocaine Dermal Filler

  4. P250020/S004 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P250020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250020

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA approvalMay 19, 2026FDA
Merz North America, Inc.PMA supplementSep 10, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Merz North America, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6501 Six Forks Rd., Raleigh, NC, 27615

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records